Company intelligence
Servier
About Servier
Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com
Verified activity
Signals from Servier
18 published signals
Presence & Recognition
Servier organized the HOPE Masterclass in Mérida for oncology experts and industry partners.
Reported by Walid Kamoun
Presence & Recognition
Servier participated in an ultra-rare epilepsy session chaired by Dr. Jacqueline French and Rima Nabbout-Tarantine at EEC2026 in Athens
Reported by Javier Avendaño, MD
Presence & Recognition
Servier announced that World Duchenne Awareness Day 2026 theme is Access Changes Lives.
Reported by Nicolas Garnier
People
Servier welcomed Hara Vassilopoulou into a new chapter as part of the company's OTC business.
Reported by Hara Vassilopoulou, MBA
Presence & Recognition
Servier's DEE Lead Dr Carlos Estevez-Fraga, MD, PhD, is discussing science with leading field experts at EEC2026
Reported by Javier Avendaño, MD
Presence & Recognition
Servier hosted a talk by PhD Fellow Ana Raquel Melo de Farias on From patients to plates: Using iPSCs to model developmental and epileptic encephalopathies and assess ASO therapeutics
Reported by Javier Avendaño, MD
People
Servier CMO Pierre Gareau celebrated his 35 years of service at the company.
Reported by Pierre Gareau
Presence & Recognition
Servier is hosting a big scientific team at the European Epilepsy Conference in Athens.
Reported by Javier Avendaño, MD
Presence & Recognition
Servier CMO Tianjin is a manufacturing partner site in Tianjin, China, that supports pharmaceutical partners seeking a trusted manufacturing partner in Asia.
Reported by Pierre Gareau
Sales & Marketing
Servier launched a new season of its BecauseIsayso campaign to raise awareness about hypertension.
Reported by Servier
Products & Services
Servier officialisé l'hébergement de GLM-5.2 sur sa propre infrastructure le 11 août 2026.
Reported by Guillaume Astor
Products & Services
Servier lançait deux nouvelles offres d'inférence le 11 août 2026.
Reported by Guillaume Astor
Products & Services
Servier généralisa ses Regional Endpoints en Europe ou aux États-Unis avec une majoration tarifaire de 10 % et lancé un Priority Tier avec une majoration tarifaire de 75 % le 11 août 2026.
Reported by Guillaume Astor
Presence & Recognition
Servier will be speaking at BioJapan 2026 during an engaging seminar showcasing its strategy, R&D capabilities, and oncology and neurology partnering interests.
Reported by Chloé Leprêtre
Research & Knowledge
Servier's R&D budget is 70% dedicated to oncology with a strong focus on rare cancers.
Reported by Servier
Research & Knowledge
Servier collaborates closely with patients and patient groups to gain a deeper understanding of blood cancers and their impact on lives.
Reported by Servier
Presence & Recognition
Servier employee Maryia Touzet is attending Future Pharma EU 2026 in Amsterdam to discuss data foundations and field force training.
Reported by Maryia Touzet
Presence & Recognition
Servier attended the 2026 European Society of Cardiology Congress in Munich.
Reported by David Pedelabat-Lartigau